Hypertriglyceridemia Therapy: Past, Present and Future Perspectives
Open Access
- 8 September 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9727
Abstract
Hypertriglyceridemia therapy is essential for preventing cardiovascular diseases. Fibrates belong to an important class of lipid-lowering drugs useful for the management of dyslipidaemia. By acting on the peroxisome proliferator-activated receptor (PPAR)-α, these drugs lower serum triglyceride levels and raise high-density lipoprotein cholesterol. Fibrate monotherapy is associated with a risk of myopathy and this risk is enhanced when these agents are administered together with statins. However, whereas gemfibrozil can increase plasma concentrations of statins, fenofibrate has less influence on the pharmacokinetics of statins. Pemafibrate is a new PPAR-α-selective drug considered for therapy, and clinical trials are ongoing. Apart from this class of drugs, new therapies have emerged with different mechanisms of action to reduce triglycerides and the risk of cardiovascular diseases.Keywords
This publication has 84 references indexed in Scilit:
- Plozasiran (ARO-APOC3) for Severe HypertriglyceridemiaJAMA Cardiology, 2024
- Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐AnalysisClinical Pharmacology & Therapeutics, 2024
- Updates in Drug Treatment of Severe HypertriglyceridemiaCurrent Atherosclerosis Reports, 2023
- Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?Current Atherosclerosis Reports, 2021
- Lipid Lowering Drugs: Present Status and Future DevelopmentsCurrent Atherosclerosis Reports, 2021
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseCochrane Database of Systematic Reviews, 2020
- Three‐arm, placebo‐controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjectsPhytotherapy Research, 2019
- Potential benefits of taurine in the prevention of skeletal muscle impairment induced by disuse in the hindlimb-unloaded ratAmino Acids, 2011
- Experimental muscle pain decreases the frequency threshold of electrically elicited muscle crampsExperimental Brain Research, 2007
- Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering DrugsJAMA, 2004